Dr. Quay has served as Chief Executive Officer and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Prior to his work at the Company, Dr. Quay served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc. from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 (MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company Inc. and is currently known as Marina Biotech, Inc.). From December 2008 to April 2009, Dr. Quay was involved in acquiring the Company's assets and preparing the Company's business plan. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at the Massachusetts General Hospital, a Harvard Medical School teaching hospital, is a former faculty member of the Department of Pathology, Stanford University School of Medicine, and is a named inventor on 14 U.S. and foreign patents covering the MASCT System. He oversaw the clinical testing and regulatory filing of the MASCT device with the FDA that led to its ultimate marketing clearance. Including the patents for the MASCT System, Dr. Quay has a total of 75 U.S. patents, 98 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the FDA. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening and the Association of Pathology Informatics.
Dr. Chen has served as Chief Scientific Officer and director of the Company since the Company was incorporated in April 2009. Prior to joining the Company, Dr. Chen served as President of Ensisheim beginning in 2008, was founder and President of SC2Q Consulting Company from 2006 to 2008, and served as Head, Cell Biology, Nastech Pharmaceuticals Company, Inc. from 2002 to 2006. During 1995 and 1996, she was an Associate Professor at National Yang Ming University, Taipei, Taiwan, and served as the principal investigator of an NIH RO1 grant studying tumor suppression by gap junction protein connexin 43 at the Department of Molecular Medicine at Northwest Hospital before working in the research department at Nastech Pharmaceutical Company. She is named as an inventor on four patent applications related to cancer therapeutics. Dr. Chen received her Ph.D. degree in microbiology and public health from Michigan State University in 1992 and has published extensively on Molecular Oncology. She received her B.S. degree in medical technology from National Yang Ming University, Taipei, Taiwan in 1984.
Kyle Guse has served as our Chief Financial Officer, General Counsel and Secretary since January 2013. Prior to joining the Company, Mr. Guse practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP. From October 2007 to January 2012 he was a partner at McDermott Will & Emery LLP, and from 1995 to October 2007 he practiced law at Heller Ehrman LLP. Mr. Guse has more than 20 years of experience counseling life sciences and other rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization. Mr. Guse began his career in 1987 as an accountant at Deloitte & Touche. Mr. Guse earned a B.S. in Business Administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law. Mr. Guse is a licensed Certified Public Accountant and a member of the California State Bar.
Christopher Destro has served in the role of Vice President of Sales and Marketing for Atossa Genetics since December 2012. Mr Destro has over 16 years of successful sales and client management expertise within the clinical sector of diagnostic biotechnology. From 2007 to 2011, Mr. Destro served in increasingly responsible positions including Vice President of Sales, North America, for three divisions of Magellan Biosciences, where he managed sales of automated blood culture and susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex and a blood-lead care platform for point of care testing. In July 2011, Magellan was acquired by Thermo Fisher Scientific, where Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets. Prior to joining Magellan, Mr. Destro served as Americas Sales Director for International Bioproducts from 2000 to 2007, where he managed sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.
Michael Malafronte has served as our Vice President of Operations since October of 2012. Prior to joining the company, Mr. Malafronte held the position of Director of Quality Operations at Theravance, Inc. from May 2011 to September 2012. From 2008 to 2011 he worked as the Director of Quality for Quorum Review IRB. Mr. Malafronte was the Vice President of Quality Assurance at Nastech Pharmaceuticals from August 2002 to March 2008. Prior to that, he worked in various quality management and operations positions at other companies including Alcon, Inc, Abbott Laboratories and ICOS Corporation. Mr. Malafronte earned a B.S. in Accounting from the University of Rhode Island and a B.A. in Kinesiology from the University of Washington.